TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).

被引：0
|
作者：
von Minckwitz, G. [1 ]
Cortes, J. [1 ]
Gligorov, J. [1 ]
Marschner, N. W. [1 ]
Puglisi, F. [1 ]
Vrdoljak, E. [1 ]
Duenne, A-A [1 ]
Zielinski, C. [1 ]
机构：
[1] GBG Forsch GmbH, German Breast Grp, Neu Isenburg, Germany
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-OT3-01-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-01-04
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Stroyakovskiy, D.
    Franke, F. A.
    Chlistalla, A.
    Pierga, J-Y
    Thomssen, C.
    Pritchard, K.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 286S
  • [42] SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6+selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    BMC Cancer, 11
  • [44] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    BMC CANCER, 2011, 11
  • [45] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study
    Dirix, L. Y.
    Romieu, G.
    Provencher, L.
    Grimes, D.
    de Souzo, Viana L.
    Paterson, A.
    Mauriac, L.
    Kirsch, A.
    Pernas, S.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 285S - 285S
  • [46] Pegylated liposomal doxorubicin (PILD) plus cyclophosphamide as 1st-line therapy for metastatic breast cancer in patients previously treated with anthracyclines
    Trudeau, M.
    Provencher, L.
    Panasci, L.
    Yelle, L.
    Latreille, J.
    Varidenberg, T. A.
    Rayson, D.
    Rodgers, A.
    Pouliot, J. F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 130 - 131
  • [47] First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100)
    Miller, K.
    Wang, M.
    Gralow, J.
    Dickler, M.
    Cobleigh, M. A.
    Perez, E. A.
    Shenkier, T. N.
    Davidson, N. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 77 - 78
  • [48] Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizurnab (BV) or placebo (PL) in the AVADO phase III study
    Cortes, J.
    Pivot, X.
    Schneeweiss, A.
    Wilcken, N.
    Ellis, P.
    Linderholm, B. K.
    Ribelles, N.
    Clemens, M.
    Haslbauer, F.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 115S - 115S
  • [49] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [50] Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) plus bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial
    Christoph, Zielinski C.
    Istvan, Lang
    Semir, Beslija
    Zsuzsanna, Kahan
    Inbar, Moshe J.
    Salomon, Stemmer M.
    Rodica, Anghel
    Damir, Vrbanec
    Diethelm, Messinger
    Thomas, Brodowicz
    CANCER RESEARCH, 2015, 75
12345